Kajian klinikal Leukemia di Virginia
7 kajian untuk Leukemia sedang mencari peserta di lokasi di Virginia.
Bandar di Virginia
Teks kajian rasmi (Bahasa Inggeris)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 3, Charlottesville
Mengambil pesertaFasa 3
Umur 18 hingga 71 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07504458Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Virginia School of Medicine, Charlottesville
- Virginia Cancer Specialists, Manassas
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Virginia Comprehensive Cancer Center, Charlottesville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Richmond
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06137118A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Charlottesville
- Dren Investigational Site, Fairfax
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Jun 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Virginia Commonwealth University/Massey Cancer Center, Richmond
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.